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2002 were obtained from Minnesota’s Department of Human
Services. Cost estimates include nursing and ancillary staff care,
as well as room and board. Costs are reported in 2002 US$.
RESULTS: Of the 3548 ischemic stroke cases identiﬁed in 1995,
618 qualiﬁed for analysis. Of those, 74% were female and the
mean age was 84 years (range: 37–102). The proportion of res-
idents in the low and medium dependency levels decreased from
37% to 22% over 6 years; whereas, the high dependency group
rose from 63% to 78%. In 2000, signiﬁcantly (p = 0.001) more
of the cohort was noted as physically and/or mentally incapable
of self-preservation than in 1995. On average, this increase in
care needs resulted in an additional annual cost of $3650 per
resident by the end of the 6-year period and roughly $2.25
million for the cohort. CONCLUSIONS: Stroke patients resid-
ing in nursing homes continue to deteriorate both physically and
mentally over time, resulting in increased care needs and costs.
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THROMBOEMBOLIC EVENT RATES IN PATIENTS WITH
NONVALVULAR ATRIAL FIBRILLATION IN THE GENERAL
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OBJECTIVES: A large proportion of patients with nonvalvular
atrial ﬁbrillation (NVAF) remain untreated with warfarin. We
aimed to compare survival and adverse outcome in patients with
NVAF treated with or without warfarin. METHODS: A number
of data sources were linked from a large population in the UK
from 1995 to 2000. Adverse events were characterised from
inpatient and death records. Survival was estimated using
Kaplan-Meier and Cox proportional hazards models, and com-
parisons between event rates using logistic or Poisson regression
and the Sign test. Patients were assumed to be receiving warfarin
if they had more than four INR measurements. RESULTS: We
identiﬁed 6108 patients with NVAF, of whom 36.4% received
warfarin. Mean survival in warfarin and non-warfarin groups
was 52.0 months and 38.2 months, respectively (p < 0.001), and
14.4 months (p < 0.001) after adjustment for confounding
factors. Warfarin patients in the upper quartile of INR control
had signiﬁcantly longer survival (57.5 months) compared with
those in the lowest quartile of control (38.1 months; p < 0.001).
The risk of stroke in the warfarin group when on treatment was
lower than that in the non-warfarin group (Relative Rate = 0.74,
p < 0.001). The risk of death from ischaemic stroke was lower
(RR = 0.43; p < 0.001) and there was a lower risk of all ischaemic
and embolic events (RR = 0.74; p < 0.001) in the warfarin group
when on treatment compared to the non-warfarin group. Risk
of bleeding in the warfarin group on treatment was greater com-
pared to the non-warfarin group (RR = 1.78; p = 0.001). CON-
CLUSIONS: These data suggest that failure to treat according to
guidelines in routine clinical practice, both in terms of patients
selected for anticoagulation and difﬁculty maintaining those
selected patients within the recommended target INR range of
2.0–3.0, is associated with additional mortality and morbidity in
patients with NVAF.
INFECTION
IN1
IMPACT OF RECENT RITONOVIR RE-PRICING ON COST-
EFFECTIVENESS ANALYSIS
Becker RV, Stegman J
Ovation Research Group, Highland Park, IL, USA
OBJECTIVES: Recent re-pricing of the ritonovir (RTV) has 
been criticized as making the antiretroviral drug unaffordable.
These criticisms generally considered only cost and not cost-
effectiveness. Our study re-evaluates a previous cost-effectiveness
analysis of RTV while considering re-pricing. METHODS: A
previous cost-effectiveness analysis of HIV salvage regimens sug-
gested that therapy including RTV is cost-effective ($37,889 per
responding patient), although slightly less cost-effective than a
similar regimen using nelﬁnavir (NFV) ($31,476) (Becker R,
Shakur I, “Cost-effectiveness of salvage therapy with delavirdine
in NNRTI-naïve patients failing indinavir,” (abs.) Int. Conf. On
AIDS, Barcelona, Spain 2002.). Our present study applied 2003
drug prices for the two regimens (RTV + saquinivir [SQV] + ade-
fovir [ADV] and NFV + SQV + ADV) with and without delavir-
dine (DLV) to determine the total drug cost with each regimen.
The cost of RTV reﬂected recent re-pricing from $8.25 to $34.28
per dose. As with the previous study, results from the ACTG 359
trial were used to calculate the cost-effectiveness of the three-
drug regimens versus the four-drug regimens over a 48-week
timeframe. The results were compared to the earlier results and
sensitivity analyses were run. RESULTS: At 48 weeks, the 2003
cost-effectiveness of treating with a 4-drug combination includ-
ing RTV was $60,963 per responding patient. This reﬂects a
60.1% increase from the regimen’s incremental cost effectiveness
ratio (ICER) in the earlier study. In contrast, the four-drug com-
bination with NFV had an ICER of $34,310, or a 9.0% increase
over the combination’s ratio in the previous study. CONCLU-
SIONS: The re-pricing of RTV has a signiﬁcant impact on cost-
effectiveness analysis involving the drug. This analysis illustrates
that studies once showing RTV to be cost-effective may now
show less cost-effective compared to other regimens given
current prices. Other prior cost-effectiveness studies that
included RTV should be re-analyzed in light of the new pricing.
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OBJECTIVES: To investigate the net return to employers in the
UK of providing antiviral inﬂuenza treatment for their employ-
ees to reduce the impact of inﬂuenza epidemics on work par-
ticipation and productivity. METHODS: A probabilistic
decision-analytic model was developed to investigate the cost-
beneﬁt of providing inﬂuenza treatment compared to sympto-
matic treatment for a healthy adult working population (18–64
years) from the employer’s perspective. Data from clinical trials,
the literature and published UK sources were used. The human
capital approach, based on average income, was used to value
an employee’s work absenteeism due to illness. Characteristics
of ﬁrms and markets that determine how the gross beneﬁts of
reduced work absenteeism are distributed between employer and
employees are taken into account in one-way sensitivity analy-
ses additionally to the probabilistic framework. RESULTS: The
expected gross beneﬁt of reducing work absenteeism of £85.00
per treated employee outweighs the costs of providing inﬂuenza
treatment (£18.18), resulting in a net beneﬁt of £67.00. Sensi-
tivity analysis shows a net beneﬁt of £25.00 and a net cost of
£10.00 if the value of 1 day work loss is 50% and 10% of the
average salary respectively. If the actual work loss is only 30%
of the days to return to normal activity the intervention results
in a net beneﬁt of £13.00. However, if work loss is 30% of the
days to return to normal activity and the value of work loss is
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only 50% of the average salary the costs outweigh the beneﬁt.
CONCLUSIONS: The beneﬁt to an employer depends on the
organization of the company and the value of reducing illness
related work absence. These results indicate that providing
inﬂuenza treatment may be a cost-saving intervention for
employers. In addition, employees will beneﬁt from improved
quality of life.
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OBJECTIVES: In immunocompromised patients, presumed 
systemic fungal infections (SFI) are treated empirically with an
intravenous (IV) antifungal to reduce the occurrence of docu-
mented infections and associated mortality. Amphotericin B (AB)
remains the treatment of choice. The toxicity of conventional AB
(CAB) often results in discontinuation or suboptimal dosing.
Liposomal or lipid formulations of AB (LAB), with improved
toxicity proﬁle, are extremely expensive. The objective was to
compare the cost-effectiveness of intravenous itraconazole
(IVitra) with CAB and LAB as empirical treatment of presumed
SFI in neutropenic cancer and bone marrow transplant (BMT)
patients. METHODS: A medical decision tree was developed,
including probabilities of toxicity, response, pathogen documen-
tation and 2nd line treatments. Clinical data were obtained from
randomized trials comparing IVitra with CAB (n = 392) and CAB
with LAB (n = 687). Resource use was obtained via modiﬁed
Delphi consensus panel, unit costs from ofﬁcial sources (public
payer perspective). Cost-effectiveness was expressed as cost 
per additional “responder” (deﬁned as patient without fever or
major toxicity). RESULTS: The total cost per neutropenic cancer
patient was lowest for IVitra (7486€), followed by CAB (9721€)
and LAB (11,956€). The same cost ranking was obtained in BMT
patients, however with higher hospitalization costs. The vari-
ables accounting for cost differences between strategies were 1st
and 2nd line antifungal drug costs. In cost-effectiveness analysis,
IVitra was dominant over CAB combining greater “effective-
ness” (because of less toxicity) and lower costs. The incremen-
tal cost-effectiveness ratios for LAB over IVitra in neutropenic
cancer and BMT patients were 188,638€/“responder” and
206,865€/“responder” respectively. CONCLUSIONS: IVitra
was shown to be a cost-effective empirical treatment for pre-
sumed SFI in neutropenic cancer and BMT patients and to be
cost saving compared to both CAB and LAB. These conclusions
are similar to those for UK, Germany, Italy and Sweden, in which
the same analysis was performed earlier.
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OBJECTIVES: Most decision-analyses for chronic hepatitis C
(CHC) treatment ignore co-morbid illness associated with CHC,
leading to overly optimistic results. Therefore, we sought: 1) to
predict population-based clinical and economic burden of CHC
and associated diseases for the next 20 years in Germany, and
2) to examine the potential impact of different antiviral treat-
ment (AVT) policies. METHODS: The German Hepatitis C
Model (GEHMO), a validated and published CHC Markov
model, was linked to German CHC prevalence and incidence
data to project the morbidity, mortality and costs for all treat-
able patients with known CHC and elevated transaminases in
Germany. The model considered HCV genotype and CHC-asso-
ciated diseases (e.g., HIV co-infection, hemophilia, extra-hepatic
manifestations) and evaluated the following policies: 1) no AVT,
2) interferon monotherapy, and 3) interferon plus ribavirin, and
(4) pegylated interferon plus ribavirin. For each policy, the model
calculated the incidence of clinical complications, CHC-related
deaths, population life years (LY), quality-adjusted life years
(QALY), costs, and incremental cost-effectiveness ratios (ICER).
We used treatment efﬁcacy data from meta-analyses of random-
ized clinical trials and literature-based epidemiologic data on co-
morbidities. We adopted a societal perspective with a 3% annual
discount rate. RESULTS: In the absence of AVT during the next
20 years, HCV would cause more than 16,000 CHC-related
deaths and 29,000 cases of liver cirrhosis leading to 1200 liver
transplantations. Peginterferon plus ribavirin would prevent
about half of these complications and would add about 53,000
LY (or 49,000 QALYs) at a total cost of 1.3€ billion (undis-
counted values). In the discounted lifetime analysis, peginter-
feron plus ribavirin was the most effective strategy with an ICER
of 23,000€/QALY compared with interferon monotherapy (next
non-dominated strategy). CONCLUSIONS: Incorporating co-
morbid illnesses associated with CHC increased the ICER 
of peginterferon plus ribavirin, but treatment remained cost-
effective and would halve the burden of disease.
METHODS & CONCEPTS I
MC1
COMPLIANCE,ADHERENCE,AND PERSISTENCE:
A COMPARISON OF THREE METHODOLOGIES FOR
EVALUATING PATIENT COMPLIANCE USING PRESCRIPTION
CLAIMS DATA
LaFleur J,Thompson C, Biskupiak J, Stockdale W, Oderda GM,
Brixner D
University of Utah, Salt Lake City, UT, USA
OBJECTIVE: To evaluate three measures of compliance by
applying established methodologies for each to one population.
METHODS: Prescription claims data for 1164 patients receiv-
ing a chronic lipid-lowering medication (a combination product
versus a statin) in 2002–2003 were obtained; MPRs, PDCs, and
ELPTs were calculated. Because each method has different inclu-
sion criteria, the measures were analyzed for three different
subsets of the overall population. A second set of analyses was
conducted on a fourth subset of patients (those included in all
three of the other analyses) to evaluate the impact of inclusion
criteria on the endpoints. Logistic regression analyses were con-
ducted for each measure to determine the probability of being
categorized as “compliant” by established deﬁnitions. RESULTS:
The results differed depending on the methodology used, sug-
gesting each measure evaluates a different aspect of overall com-
pliance. MPR analysis demonstrated higher overall compliance
rates with the combination product versus statins (p = 0.001).
PDC analysis demonstrated lower compliance rates with the
combination product versus statins (2nd quarter p = 0.003, 4th
quarter p = 0.011). ELPT analysis also demonstrated lower com-
pliance rates for the combination product versus statins (6th
